Morphea en coup de sabre and hemifacial atrophy in an interdisciplinary approach
Journal of Face Aesthetics · 2020
DOI: 10.20883/jofa.35 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Face Aesthetics, 2020. Verfasst von Agnieszka Wróblewska und 6 weiteren Autor:innen.
Abstract (Originalsprache)
The increase in the degree of fluctuation asymmetry is accompanied, among others, by diseases such as morphea en coup de sabre (morphea ECDS) or Parry‑Romberg syndrome (PHA). Patients suffering from them struggle not only with dermatological defects, but also with neurological, rheumatological, orthopedic, ophthalmological and dental symptoms. Morphological and functional disorders and craniofacial deformities related to them often generate psychosocial problems. The complexity of the issues to be solved proves the necessity of undertaking interdisciplinary actions aimed at developing objective diagnostic and therapeutic protocols, restoring (especially in pediatric patients) as close as possible to the correct developmental patterns, inhibiting the active phase of the disease and undertaking effective and aesthetically satisfying measures.
Zitieren
APA
Wróblewska, A., Polańska, A., Dańczak‑Pazdrowska, A., Żaba, R., Adamski, Z., Metthews‑Brzozowska, T., & Wegner, J. (2020). Morphea en coup de sabre and hemifacial atrophy in an interdisciplinary approach. Journal of Face Aesthetics. https://doi.org/10.20883/jofa.35
Vancouver
Wróblewska A, Polańska A, Dańczak‑Pazdrowska A, Żaba R, Adamski Z, Metthews‑Brzozowska T, et al. Morphea en coup de sabre and hemifacial atrophy in an interdisciplinary approach. Journal of Face Aesthetics. 2020. doi:10.20883/jofa.35
BibTeX
@article{Wrblewska2020,
author = {Wróblewska, Agnieszka and Polańska, Adriana and Dańczak‑Pazdrowska, Aleksandra and Żaba, Ryszard and Adamski, Zygmunt and Metthews‑Brzozowska, Teresa and Wegner, Joanna},
title = {Morphea en coup de sabre and hemifacial atrophy in an interdisciplinary approach},
journal = {Journal of Face Aesthetics},
year = {2020},
doi = {10.20883/jofa.35}
}
EUVIMED